Catch up with the latest happenings at Terremoto.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
/in 2026, Press Release/by eallisonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences Appoints James Christensen, Ph.D., as President, Head of Research & Development
/in 2025, Press Release/by gmooreTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
/in 2024, Press Release/by gmooreTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences Closes $175 Million Series B Financing
/in 2023, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
/in 2022, Press Release/by eallisonTerremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.